Clinical Trial Update: The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, pharmacokinetics, and antitumor activity of BGB-A317 in combination with BGB-290 in advanced solid tumors; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BGB-290
• BGB-A317 (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2021-12-06